VFA
XLRN

Virtus Fund Advisers’s Acceleron Pharma XLRN Stock Holding History

Virtus Fund Advisers’s Portfolio XLRN Stock Details XLRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		$414K Buy
+9,748
New +$366K ﹤0.01% 343
2014
Q3 		– Sell
-1,403
Closed -$48K – 2153
2014
Q2 		$48K Buy
+1,403
New +$46.9K ﹤0.01% 1899

Other funds holding XLRN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Virtus Fund Advisers's XLRN Position: Q4 2017 in Review

Virtus Fund Advisers opened a new position in Acceleron Pharma (XLRN) in Q4 2017: 9,748 shares worth $414K. The stake represents ﹤0.01% of the portfolio and ranks #343 among its holdings. This is a return to the name: Virtus Fund Advisers previously reported a position in XLRN as recently as Q2 2014.

Virtus Fund Advisers first reported a position in XLRN in Q2 2014 and has held it in 2 quarters since. 137 funds tracked by Wall St. Rank hold XLRN as of Q4 2017.

  • Virtus Fund Advisers held 9,748 shares of Acceleron Pharma worth $414K as of Q4 2017.
  • Acceleron Pharma was a new Virtus Fund Advisers position in Q4 2017.
  • Acceleron Pharma made up ﹤0.01% of Virtus Fund Advisers's portfolio in Q4 2017, its #343 holding.
  • Virtus Fund Advisers first reported a position in Acceleron Pharma in Q2 2014 and has held it in 2 quarters since.
  • 137 funds tracked by Wall St. Rank held Acceleron Pharma as of Q4 2017.

Based on Virtus Fund Advisers's 13F filing for Q4 2017, filed 9 Feb 2018.